Akela Pharma Inc., of Vancouver, British Columbia, said it applied for voluntary delisting from the Toronto Stock Exchange, citing an inability to maintain the continuous listing requirements...Its expenses related to the terminations will be $280,000 in the fourth quarter

Eisai Inc., of Woodcliff Lake, N.J., said the FDA accepted for priority review Eisai's NDA for AcipHex Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of gastroesophageal reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age

Details Date Advaxis Inc. (Princeton, N.J.) Private placement N/A $10 Advaxis secured $10M in equity financing from Magna Group LLC 11/1/12 Amarantus BioSciences Inc. (Sunnyvale, Calif.) Private placement N/A $1.1 Amarantus secured $1.1M in funding through two separate transactions, by issuing a convertible promissory note to an undisclosed investor in the principal amount of $600,000 and, with an institutional fund, settled more than $500,000 in accounts payable 11/15/12 Ambit Biosciences Inc

After the dividend distribution, expected to be paid Jan. 1, 2013, AbbVie will be an independent, publicly traded company, and Abbott will retain no ownership interest...AbbVie common stock is expected to begin trading Jan. 2, 2013, on the New York Stock Exchange under the ticker "ABBV...The recall does not affect or related to the 80-mg dosage strength of the cholesterol-lowering drug

Those and other data are set to be presented at the American Society for Hematology meeting in Atlanta next month...Should the trial hit the predefined overall survival endpoint, the company said it expects those data to support marketing applications for AlloStim in the U.S., European Union and other jurisdictions...Under the terms, Nordic Pharma will commercialize the product in those areas, with Medigene receiving milestone payments and double-digit royalties on sales, as well as certain payments

Forest Laboratories Inc., of New York, and Gedeon Richter plc, of Budapest, Hungary, said Forest submitted a new drug application for cariprazine, a dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, for use in schizophrenia and bipolar mania...Pfizer Inc., of New York, said it completed its acquisition of Cupertino, Calif.-based NextWave Pharmaceuticals Inc., a privately held specialty pharma firm developing products for attention deficit hyperactivity disorder

Ildong gained exclusive rights to commercialize temanogrel in South Korea for myocardial infarction, acute coronary syndrome, stroke, peripheral artery disease and other cardiovascular diseases...Arena retained ownership of temanogrel outside South Korea and the rights to use data generated by Ildong to develop and commercialize temanogrel outside South Korea by Arena or other licensees...Arena also is eligible to receive a royalty on net sales of temanogrel in South Korea, while Ildong is eligible to

Abbott, of Abbott Park, Ill., said the European Commission approved Humira (adalimumab) for the treatment of pediatric patients, ages 6 to 17, with severe active Crohn's disease who failed, are intolerant to or have contraindications to conventional therapy

The randomized, sham-controlled, blind trial will compare C3BS-CQR-1 to a sham therapy in at least 240 patients with a primary composite endpoint of mortality, morbidity, quality of life and other measures at nine months after the procedure...LEO Pharma A/S, of Ballerup, Denmark, said the European Commission granted marketing authorization for Picato (ingenol mebutate) gel as a treatment for actinic keratosis, a skin condition that can lead to squamous cell carcinoma if not treated...Following

The product is licensed from Cipher Pharmaceuticals Inc., of Mississauga, Ontario, and was formulated in such a way that it does not need to be given with a high-fat meal, as is usually the case with isotretinoin

Activiomics will apply its TIQUAS phosphoproteomics platform to elucidate signaling mechanisms of lead compounds in relevant cell-based systems...Erytech Pharma, of Lyon, France, said it entered a definitive agreement granting Orphan Europe, part of the Recordati Group, of Milano, Italy, exclusive rights for the commercialization and distribution of Graspa in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) in Europe...The TGA approval will enable health professionals to prescribe

Novartis AG, of Basel, Switzerland, gained FDA approval of Flucelvax, described as the first cell culture-derived seasonal flu vaccine cleared for marketing in the U.S. The vaccine was approved for adults 18 years old and older.

and strategic global markets Financial terms were not disclosed 9/12/12 Oxford BioMedica plc (Oxford, UK) Immune Design Corp. (Seattle) ND Master services deal to use Oxford BioMedica's expertise in lentiviral vector clinical development for Immune Design's therapeutic vaccine candidate for cancer and other chronic diseases Financial terms were not disclosed 9/28/12 QLT Inc. (Vancouver, British Columbia) Valeant Pharmaceuticals International Inc. (Montreal) $112.5 Sale of wet, age-related

LEO Pharma A/S, of Ballerup, Denmark, said the European Commission granted marketing authorization for Picato (ingenol mebutate) gel as a treatment for actinic keratosis, a skin condition that can lead to squamous cell carcinoma if not treated...Following completion of those programs, the pharma firm will have an exclusive option to license rights in exchange for development and commercial milestones payments and royalties

In other news, Orexo said the FDA accepted for review its new drug application for Zubsolv, a sublingual formulation of buprenorphine and naloxone, and set a PDUFA date of July l6, 2013...Tiltan Pharma Ltd., of Jerusalem, said it enrolled the first U.S

Friday's positive news does not trigger any milestone payment from Sanofi to Copenhagen, Denmark-based Zealand, but it can still take in $215 million in development and commercial milestones, including $40 million for a depot formulation of Lyxumia...Its safety and tolerability profile appears similar to other members of its class, with transient nausea, vomiting and diarrhea among the most common side effects...Other safety issues, according to the EMA, including hypoglycemia when Lyxumia was

Janssen-Cilag International NV, of Beerse, Belgium, part of Johnson & Johnson, said the European Committee for Medicinal Products for Human Use granted a positive opinion recommending approval of Zytiga (abiraterone acetate) for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in men who are asymptomatic or mildly symptomatic after failure of androgen-deprivation therapy and in whom chemotherapy is not yet clinically

The acquisition is set to close later this year and is expected to complement Allergan's existing facial aesthetics business, which includes Botox Cosmetic, Juvederm and Latisse...Allergan said it expects to operate SkinMedica as a separate global business

Friday's positive news does not trigger any milestone payment from Sanofi to Copenhagen, Denmark-based Zealand, but it can still take in $215 million in development and commercial milestones, including $40 million for a depot formulation of Lyxumia...Its safety and tolerability profile appears similar to other members of its class, with transient nausea, vomiting and diarrhea among the most common side effects...Other safety issues, according to the EMA, including hypoglycemia when Lyxumia was